Gut microbiota metabolite trimethylamine N-oxide promoted NAFLD progression by exacerbating intestinal barrier disruption and intrahepatic cellular imbalance
International Immunopharmacology · 2024-12 · 142 · 113173
DOI: 10.1016/j.intimp.2024.113173 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024-12. Verfasst von Fulin Nian und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Gastroenterology, Shanghai Pudong…. Hauptthemen laut MEDLINE: Methylamines, Non-alcoholic Fatty Liver Disease, Gastrointestinal Microbiome, Liver. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide, with the gut microbiota and its metabolites are important regulators of its progression. Trimethylamine N-oxide (TMAO), a metabolite of the gut microbiota, has been closely associated with various metabolic diseases, but its relationship with NAFLD remains to be elucidated. In this study, we found that fecal TMAO levels correlated with NAFLD severity. Moreover, TMAO promoted lipid deposition in HepG2 fatty liver cells and exacerbated hepatic steatosis in NAFLD rats. In the colon, TMAO undermined the structure and function of the intestinal barrier at various levels, further activated the TLR4/MyD88/NF-κB pathway, and inhibited the WNT/β-catenin pathway. In the liver, TMAO induced endothelial dysfunction with capillarization of liver sinusoidal endothelial cells, while modulating macrophage polarization. In conclusion, our study suggests that gut microbiota metabolite TMAO promotes NAFLD progression by impairing the gut and liver and that targeting TMAO could be an alternative therapeutic strategy for NAFLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Gastroenterology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
- Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Gastroenterology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
- Department of Gastroenterology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China. Electronic address: xiaolan_lu@163.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Nian, F., Chen, Y., Xia, Q., Zhu, C., Wu, L., & Lu, X. (2024). Gut microbiota metabolite trimethylamine N-oxide promoted NAFLD progression by exacerbating intestinal barrier disruption and intrahepatic cellular imbalance. International Immunopharmacology, 142, 113173. https://doi.org/10.1016/j.intimp.2024.113173
Vancouver
Nian F, Chen Y, Xia Q, Zhu C, Wu L, Lu X. Gut microbiota metabolite trimethylamine N-oxide promoted NAFLD progression by exacerbating intestinal barrier disruption and intrahepatic cellular imbalance. International Immunopharmacology. 2024;142:113173. doi:10.1016/j.intimp.2024.113173
BibTeX
@article{Nian2024,
author = {Nian, Fulin and Chen, Yueying and Xia, Qiaoyun and Zhu, Chen and Wu, Longyun and Lu, Xiaolan},
title = {Gut microbiota metabolite trimethylamine N-oxide promoted NAFLD progression by exacerbating intestinal barrier disruption and intrahepatic cellular imbalance},
journal = {International Immunopharmacology},
year = {2024},
volume = {142},
pages = {113173},
doi = {10.1016/j.intimp.2024.113173}
}
EUVIMED